|
KMID : 0882420100790050506
|
|
Korean Journal of Medicine
2010 Volume.79 No. 5 p.506 ~ p.508
|
|
|
Sunitinib-induced hypothyroidism
|
|
Jung Yoon-Jae
|
|
|
Abstract
|
|
|
|
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor that is effective for advanced renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor. Currently, sunitinib is being investigated in multiple other tumor types including non-small cell lung cancer, breast cancer, colon cancer, and endocrine tumors. Recent studies have shown that sunitinib induces thyroid dysfunction, mainly hypothyroidism during treatment. The incidence of sunitinib-induced hypothyroidism has been reported to be 36~85%. Although several hypotheses have been suggested, the mechanisms by which sunitinib induces hypothyroidism are not clear. As considered the fairly high incidence of sunitinib-induced hypothyroidism, thyroid function should be regularly monitored in all patients treated with sunitinib.
|
|
|
KEYWORD
|
|
|
Sunitinib, Tyrosine kinase inhibitor, Hypothyroidism
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|